

#3/I.D.S.

Sheet 1 (A) of 7

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/153		SERIAL NO. 10/068,067	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (See several sheets if necessary)				APPLICANT Marc E. Rothenberg et al.			
				FILING DATE February 5, 2002		GROUP 1642	
(37 CFR 1.906) U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER		ISSUE DATE	PATENTEE	CLASS	FILING DATE IF APPROPRIATE
<i>PR</i>	A.A	6	4 0 3 7 8 2	06/11/02	Luster et al.	536 23.5	08/04/99
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L						
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
<i>PR</i>	A.R	Amara et al., HIV Coreceptor Downregulation as Antiviral Principle: SDF-1a-dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication, J. Exp. Med., 186(1), July 7, 1997, 139-146.					
<i>PR</i>	A.S	Bertrand and Ponath, CCR3 Blockade as a New Therapy for Asthma, Exp. Opin. Invest. Drugs, 9(1), 2000, 43-52					
<i>PR</i>	A.T	Combadiere et al., Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor, Journal of Biological Chemistry, 270(27), July 14, 1995, 16491-16494.					
EXAMINER <i>Proctor</i>				DATE CONSIDERED <i>4/23/04</i>			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.							

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/O68,067INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Marc E. Rothenberg et al.FILING DATE
February 5, 2002GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A.						
	B.B.						
	B.C.						
	B.D.						
	B.E.						
	B.F.						
	B.G.						
	B.H.						
	B.I.						
	B.J.						
	B.K.						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L.						
	B.M.						
	B.N.						
	B.O.						
	B.P.						
	B.Q.						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	B.R.	Combadiere et al., Cloning and functional expression of a human eosinophil CC chemokine receptor, J. Biol Chem. 270(18), 11034.
JRB	B.S.	Daugherty et al., Cloning, Expression, and Characterization of the Human Eosinophil Eotaxin Receptor, J. Exp. Med., 183, May 1996, 2349-2354.
JBA	B.T.	Forster et al., Intracellular and Surface Expression of the HIV-1 Coreceptor CXCR4/Fusion on Various Leukocyte Subsets: Rapid Internalization and Recycling Upon Activation, Journal of Immunology, 160 (1998) 1522-1531.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

RECEIVED

JUL 29 2002
TECH CENTER 1600/2900

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/068,067INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Marc E. Rothenberg et al.FILING DATE
February 5, 2002GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	C.A						
	C.B						
	C.C						
	C.D						
	C.E						
	C.F						
	C.G						
	C.H						
	C.I						
	C.J						
	C.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	C.L						
	C.M						
	C.N						
	C.O						
	C.P						
	C.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

Jgm	C.R	Franci et al., <u>Phosphorylation by a G Protein-Coupled Kinase Inhibits Signaling and Promotes Internalization of the Monocyte Chemoattractant Protein-1 Receptor</u> , Journal of Immunology, 1996, 5606-5612.
Da	C.S	Hansel et al., <u>An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils</u> , Journal of Immunological Methods, 145 (1991) 105-110.
JBW	C.T	Matthews et al., <u>Eotaxin is Required for the Baseline Level of Tissue Eosinophils</u> , Proc. Natl. Acad. Sci. USA: Immunology, 95, May 1998, 6273-6278

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered.
Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/O68,067INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Marc E. Rothenberg et al.FILING DATE
February 5, 2002GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	D.A.						
	D.B.						
	D.C.						
	D.D.						
	D.E.						
	D.F.						
	D.G.						
	D.H.						
	D.I.						
	D.J.						
	D.K.						

RECEIVED
 JUL 29 2002
 TECH CENTER 1600/2000

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	D.L.						
	D.M.						
	D.N.						
	D.O.						
	D.P.						
	D.Q.						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

JBA	D.R.	Mueller et al., <u>Activation of Protein Kinase C Enhances the Phosphorylation of the Type B Interleukin-8 Receptor and Stimulates Its Degradation in Non-hematopoietic Cells</u> , Journal of Biological Chemistry, 270(18), May 5, 1995, 10439-10448.					
JBA	D.S.	Ponath et al., <u>Molecular Cloning and Characterization of a Human Eotaxin Receptor Expressed Selectively on Eosinophils</u> , J. Exp. Med., 183, June 1996, 2437-2448.					
JBA	D.T.	Rothenberg, <u>Eosinophilia</u> , New England Journal of Medicine, 338, May 28, 1998, 1592-1600.					

EXAMINER

DATE CONSIDERED

JBA

7/23/04

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/O68,067INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Marc E. Rothenberg et al.FILING DATE
February 5, 2002GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	E.A.						
	E.B.						
	E.C.						
	E.D.						
	E.E.						
	E.F.						
	E.G.						
	E.H.						
	E.I.						
	E.J.						
	E.K.						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	E.L.					
	E.M.					
	E.N.					
	E.O.					
	E.P.					
	E.Q.					

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

E.R.	Rothenberg et al., <u>Targeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-Induced Tissue Eosinophilia</u> , J. Exp. Med., 185(4) February 17, 1997, 785-790
E.S.	Sallusto et al., <u>Selective Expression of the Eotaxin Receptor CCR3 by Human T Helper 2 Cells</u> , Science, 277(5334), September 26, 1997, 2005-2007.
E.T.	Samanta et al., <u>Interleukin 8 (Monocyte-derived Neutrophil Chemotactic Factor) Dynamically Regulates Its Own Receptor Expression on Human Neutrophils</u> , Journal of Biological Chemistry, 265(1), Jan. 5, 1990, 183-189.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/O68,067INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Marc E. Rothenberg et al.FILING DATE
February 5, 2002GROUP
1642




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	F.A.						
	F.B.						
	F.C.						
	F.D.						
	F.E.						
	F.F.						
	F.G.						
	F.H.						
	F.I.						
	F.J.						
	F.K.						


FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	F.L.						
	F.M.						
	F.N.						
	F.O.						
	F.P.						
	F.Q.						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	F.R.	Solari et al., <u>Receptor-mediated Endocytosis of CC-chemokines</u> , Journal of Biological Chemistry, 272(15), Apr. 11, 1997, 9617-9620.
	F.S.	Uguccioni et al., <u>High Expression of the Chemokine Receptor CCR3 in Human Blood Basophils, Role in Activation by Eotaxin, MCP-4, and Other Chemokines</u> , J. Clin. Invest. 100(5), September 1997, 1137-1143.
	F.T.	Uhing et al., <u>Differential Regulation of cAMP by Endogenous Versus Transfected Formylpeptide Chemoattractant Receptors: Implications for G1-Coupled Receptor Signaling</u> , Biochemical and Biophysical Research Communications, 183(3), Mar. 31, 1992, 1033-1039.

EXAMINER



DATE CONSIDERED

7/23/04

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/O68,067INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Marc E. Rothenberg et al.FILING DATE
February 5, 2002GROUP
1642


U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	G.A.						
	G.B.						
	G.C.						
	G.D.						
	G.E.						
	G.F.						
	G.G.						
	G.H.						
	G.I.						
	G.J.						
	G.K.						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	G.L.						
	G.M.						
	G.N.						
	G.O.						
	G.P.						
	G.Q.						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	G.R.	Zimmermann et al., Analysis of the CC Chemokine Receptor 3 Gene Reveals a Complex 5' Exon Organization, a Functional Role for Untranslated Exon 1, and a Broadly Active Promoter with Eosinophil-Selective Elements, Blood, 96(7), October 1, 2000, 2346-2354
	G.S.	
	G.T.	

EXAMINER



DATE CONSIDERED

7/23/04

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

RECEIVED
JUL 29 2002
TECH CENTER 1600/2900

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/O68,067INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Marc E. Rothenberg et al.

(37 CFR 1.98(b))

(Use several sheets if necessary)

FILING DATE
February 5, 2002GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L						
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						






OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	A.R	Barker, et al., <u>Cloning and Sequence Analysis of the Human Gene Encoding Eosinophil Major Basic Protein</u> , Gene, 1990, 86, 285
	A.S	Daugherty, Bruce L., <u>The β-Chemokine Receptor Genes CCR1 (CMKBR1), CCR2 (CMKBR2), and CCR3 (CMKBR3) Cluster within 285 kb on Human Chromosome 3p21</u> , Genomics 41, 294-295 (1997)
	A.T	Foster, et al., <u>Elemental Signals Regulating Eosinophil Accumulation in the Lung</u> , Immunological Reviews 2001, Vol. 179: 173-181

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/153		SERIAL NO. 10/068,067	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Marc E. Rothenberg et al.			
(37 CFR 1.98(b))				FILING DATE February 5, 2002		GROUP 1642	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	B.R	Gomolin, et al., <u>Human Eosinophil Charcot-Leyden Crystal Protein: Cloning and Characterization of a Lysophospholipase Gene Promoter</u> , Blood, Vol. 82, No. 6, September 15, 1993, 1868-1874					
	B.S	Kavanaugh, et al., <u>Analysis of the CCR3 Promoter Reveals Cell-Specific Regulatory Regions Including Gata-1 Sites in Untranslated Exon 1</u> , J Allergy Clin Immunol, Abstracts, February 2001, S224					
	B.T	Leckie, et al., <u>Effects of an Interleukin-5 Blocking Monoclonal Antibody on Eosinophils, Airway Hyper-responsiveness, and the Late Asthmatic Response</u> , The Lancet, Vol. 356, December 23, 2000, 2144					
EXAMINER				DATE CONSIDERED			
							
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/068,067INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Marc E. Rothenberg et al.

(37 CFR 1.98(b))

(Use several sheets if necessary)

FILING DATE
February 5, 2002GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	C.A						
	C.B						
	C.C						
	C.D						
	C.E						
	C.F						
	C.G						
	C.H						
	C.I						
	C.J						
	C.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	C.L						
	C.M						
	C.N						
	C.O						
	C.P						
	C.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)


	C.R	Mack, et al., <u>Aminoxy-pentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity</u> , Journal of Exp. Med., 198, 1215, April 20, 1998
	C.S	McDermott, et al., <u>CCR5 Promoter Polymorphism and HIV-1 Disease Progression</u> , The Lancet, Vol. 351, September 12, 1998
	C.T	Moriuchi, et al., <u>Cloning and Analysis of the Promoter Region of CCR5, a Coreceptor for HIV-1 Entry</u> , Journal of Immunology, Vol. 159, 5441, 1997

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/153		SERIAL NO. 10/O68,067	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Marc E. Rothenberg et al.			
(Use several sheets if necessary)				FILING DATE February 5, 2002		GROUP 1642	
(37 CFR 1.98(b))							
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	D.A						
	D.B						
	D.C						
	D.D						
	D.E						
	D.F						
	D.G						
	D.H						
	D.I						
	D.J						
	D.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	D.L						
	D.M						
	D.N						
	D.O						
	D.P						
	D.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
D.R	Sun, et al., <u>Identification and Characterization of a Functional Promoter Region in the Human Eosinophil IL-5 Receptor α Subunit Gene</u> , The Journal of Biological Chemistry, Vol. 270, No. 3, January 20, 1995, 1462-1471						
D.S	Webb, et al., <u>Distinct Spatial Requirement for Eosinophil-induced Airways Hyperactivity</u> , Immunology and Cell Biology (2001) 79, 165-169						
D.T	Yamaguchi, et al., <u>Functional Characterization of the Promoter for the Gene Encoding Human Eosinophil Peroxidase</u> , The Journal of Biological Chemistry, Vol. 269, No. 30, July 29, 1994, 19410						
EXAMINER 				DATE CONSIDERED 7/23/04			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/O68,067INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Marc E. Rothenberg et al.

(37 CFR 1.98(b))

(Use several sheets if necessary)

FILING DATE
February 5, 2002GROUP
1642




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	E.A.						
	E.B.						
	E.C.						
	E.D.						
	E.E.						
	E.F.						
	E.G.						
	E.H.						
	E.I.						
	E.J.						
	E.K.						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	E.L.						
	E.M.						
	E.N.						
	E.O.						
	E.P.						
	E.Q.						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	E.R.	Yamamoto, et al., Cloning and Functional Characterization of the 5'-Flanking Region of the Human Monocyte Chemoattractant Protein-1 Receptor (CCR2) Gene, The Journal of Biological Chemistry, Vol. 274, No. 8, February 19, 1999, P. 4646
	E.S.	Zimmermann, et al., CC Chemokine Receptor-3 Undergoes Prolonged Ligand-induced Internalization*, The Journal of Biological Chemistry, Vol. 274, No. 18, April 30, 1999, pp. 12611-12618
	E.T.	Zimmermann, et al., Molecular Analysis of CCR-3 Events in Eosinophilic Cells, The Journal of Immunology, 2000, 164, 1055

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CMC/153SERIAL NO.
10/068,067SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Marc E. Rothenberg et al.

(37 CFR 1.98(b))

(Use separate sheets if necessary)

FILING DATE
February 5, 2002GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

RECEIVED

JAN 10 2003

TECH CENTER 1600/2900

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
<i>CPA</i>	A.L	WO 95/12415	11 May 1995	PCT WO	A61K 48/00	G07H 21/00	
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>JM</i>	A.R	Nirodi, et al., <u>The Role of CDP in the Negative Regulation of CXCL1 Gene Expression</u> , Journal of Biological Chemistry, Vol. 276, No. 28, July 13 2001, pp. 26122-26131.					
<i>JP</i>	A.S	Yamaguchi, et al., <u>Mechanisms of Transcription in Eosinophils: GATA-1, but not GATA-2, Transactivates the Promoter of the Eosinophil Granule Major Basic Protein Gene</u> , Blood, Vol. 91, No. 9, May 1 1998, pp. 3447-3458.					
	A.T						

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)